Published in Graefes Arch Clin Exp Ophthalmol on September 01, 2011
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice. PLoS One (2012) 0.93
Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma. PLoS One (2015) 0.91
Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS One (2013) 0.81
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion promotes cancer growth in TRAMP prostate cancer prone mice. PLoS One (2015) 0.76
In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget (2016) 0.75
Downregulation of growth differentiation factor-15 in trichostatin A-induced apoptosis could play a role in progression of gastric cancer. Int J Clin Exp Pathol (2015) 0.75
The biology of uveal melanoma. Cancer Metastasis Rev (2017) 0.75
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A (1997) 4.20
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res (2004) 3.83
Prognostic implications of monosomy 3 in uveal melanoma. Lancet (1996) 3.26
Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol (2001) 2.52
Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol (2001) 2.38
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology (2003) 2.10
Endoresection of choroidal melanoma. Br J Ophthalmol (1998) 2.00
The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology (1993) 1.91
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res (2006) 1.79
Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol (2008) 1.76
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res (2003) 1.71
Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology (2007) 1.68
A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol (1983) 1.67
Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem (2000) 1.58
Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res (2003) 1.45
Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res (2003) 1.31
Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci (2009) 1.25
Transpupillary thermotherapy for choroidal melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology (1998) 1.22
Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol (1997) 1.16
Screening for metastatic malignant melanoma of the uvea revisited. Cancer (1999) 1.10
Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol (2002) 1.05
Targeted therapy for uveal melanoma. Cancer Treat Rev (2008) 1.03
Serum markers to detect metastatic uveal melanoma. Anticancer Res (2007) 1.00
Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci (2006) 1.00
The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res (2005) 0.98
Predictive power of screening tests for metastasis in uveal melanoma. Eye (Lond) (1998) 0.94
Liver function tests in metastatic uveal melanoma. Am J Ophthalmol (2004) 0.92
Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. J Biol Chem (2002) 0.85
Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol (2010) 0.84
Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res (2002) 0.82
Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol (2006) 0.80
"Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol (2005) 0.78
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain (2008) 2.57
Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy. Nat Genet (2004) 2.40
CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet (2005) 2.37
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension (2004) 2.32
Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet (2002) 2.10
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist (2011) 2.05
Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival. Am J Pathol (2013) 2.02
Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol (2013) 1.99
Cone dystrophy with supernormal rod response: novel KCNV2 mutations in an underdiagnosed phenotype. Ophthalmology (2013) 1.99
TRPM1 is mutated in patients with autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet (2009) 1.93
A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain (2007) 1.82
Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res (2010) 1.80
Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol (2011) 1.78
Mutations in CABP4, the gene encoding the Ca2+-binding protein 4, cause autosomal recessive night blindness. Am J Hum Genet (2006) 1.77
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology (2007) 1.68
The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol Cell Neurosci (2003) 1.67
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene. Proc Natl Acad Sci U S A (2009) 1.64
Development of a genotyping microarray for Usher syndrome. J Med Genet (2006) 1.63
Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc Biol Sci (2013) 1.63
Mutation analysis of NR2E3 and NRL genes in Enhanced S Cone Syndrome. Hum Mutat (2004) 1.45
Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol (2007) 1.41
Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. Ann Neurol (2004) 1.40
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology (2008) 1.37
A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia. Am J Hum Genet (2012) 1.36
Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with perivascular retinal pigment epithelium atrophy. Am J Hum Genet (2007) 1.33
Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy. Am J Hum Genet (2006) 1.29
Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Hum Mol Genet (2005) 1.26
X-linked retinitis pigmentosa: RPGR mutations in most families with definite X linkage and clustering of mutations in a short sequence stretch of exon ORF15. Invest Ophthalmol Vis Sci (2003) 1.25
Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci (2009) 1.25
Whole-exome sequencing identifies mutations in GPR179 leading to autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet (2012) 1.25
Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol (2006) 1.25
Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci (2010) 1.23
Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey. Acta Ophthalmol (2012) 1.22
Morphology and functional characteristics in adult vitelliform macular dystrophy. Retina (2004) 1.22
Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal photoreceptor degeneration. Hum Mol Genet (2004) 1.22
Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol (2005) 1.22
Mutation analysis identifies GUCY2D as the major gene responsible for autosomal dominant progressive cone degeneration. Invest Ophthalmol Vis Sci (2008) 1.21
The histone acetyltransferase p300 promotes intrinsic axonal regeneration. Brain (2011) 1.21
CNGB3 achromatopsia with progressive loss of residual cone function and impaired rod-mediated function. Invest Ophthalmol Vis Sci (2007) 1.21
Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. J Cataract Refract Surg (2008) 1.20
Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol (2007) 1.18
Mutations in the GUCA1A gene involved in hereditary cone dystrophies impair calcium-mediated regulation of guanylate cyclase. Hum Mutat (2009) 1.14
Long-term outcome of primary endoresection of choroidal melanoma. Br J Ophthalmol (2013) 1.13
Mutations in C8orf37, encoding a ciliary protein, are associated with autosomal-recessive retinal dystrophies with early macular involvement. Am J Hum Genet (2011) 1.12
Safety profile of bevacizumab on cultured human corneal cells. Cornea (2007) 1.12
Genotyping microarray for CSNB-associated genes. Invest Ophthalmol Vis Sci (2009) 1.10
Prevalence of myocilin and optineurin sequence variants in German normal tension glaucoma patients. Mol Vis (2005) 1.10
Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci (2008) 1.09
Molecular analysis of uveal melanoma. Ophthalmology (2013) 1.08
Novel types of mutation in the choroideremia ( CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon. Hum Genet (2003) 1.07
Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci (2011) 1.06
BBS1 mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. Arch Ophthalmol (2012) 1.06
Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Experiment Ophthalmol (2008) 1.06
Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum Gene Ther (2013) 1.06
Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol (2009) 1.05
Restoration of useful vision up to letter recognition capabilities using subretinal microphotodiodes. Conf Proc IEEE Eng Med Biol Soc (2010) 1.05
Blue cone monochromatism: clinical findings in patients with mutations in the red/green opsin gene cluster. Graefes Arch Clin Exp Ophthalmol (2004) 1.05
Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res (2011) 1.05
Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol (2007) 1.04
Mutations in RAB28, encoding a farnesylated small GTPase, are associated with autosomal-recessive cone-rod dystrophy. Am J Hum Genet (2013) 1.03
Thirty distinct CACNA1F mutations in 33 families with incomplete type of XLCSNB and Cacna1f expression profiling in mouse retina. Eur J Hum Genet (2002) 1.03
ABCA4 gene analysis in patients with autosomal recessive cone and cone rod dystrophies. Eur J Hum Genet (2008) 1.02
Management of patients with uveal metastases at the Liverpool Ocular Oncology Centre. Br J Ophthalmol (2013) 1.02
Mutations in CNGA3 impair trafficking or function of cone cyclic nucleotide-gated channels, resulting in achromatopsia. Hum Mutat (2008) 1.01
A tale of two retinal domains: near-optimal sampling of achromatic contrasts in natural scenes through asymmetric photoreceptor distribution. Neuron (2013) 1.01
A new small-incision technique for injector implantation of transsclerally sutured foldable lenses. Ophthalmic Surg Lasers Imaging (2007) 0.99
Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia. Hum Mol Genet (2010) 0.98
Novel mutations of FOXC1 and PITX2 in patients with Axenfeld-Rieger malformations. Invest Ophthalmol Vis Sci (2006) 0.98
Comprehensive cDNA study and quantitative transcript analysis of mutant OPA1 transcripts containing premature termination codons. Hum Mutat (2008) 0.97
Tyrosinase biosynthesis in adult mammalian retinal pigment epithelial cells. Exp Eye Res (2006) 0.97
Identification of a locus on chromosome 2q11 at which recessive amelogenesis imperfecta and cone-rod dystrophy cosegregate. Eur J Hum Genet (2002) 0.97
Lysyl oxidase-like 1 gene polymorphisms in German patients with normal tension glaucoma, pigmentary glaucoma and exfoliation glaucoma. J Glaucoma (2010) 0.97
Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol (2008) 0.96
Rare primary mitochondrial DNA mutations and probable synergistic variants in Leber's hereditary optic neuropathy. PLoS One (2012) 0.96
OPA1, the disease gene for autosomal dominant optic atrophy, is specifically expressed in ganglion cells and intrinsic neurons of the retina. Invest Ophthalmol Vis Sci (2004) 0.96
Artificial neural networks estimating survival probability after treatment of choroidal melanoma. Ophthalmology (2008) 0.95
Clinical features of achromatopsia in Swedish patients with defined genotypes. Ophthalmic Genet (2002) 0.94
Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol (2005) 0.94
Identification of a novel CRYBB2 missense mutation causing congenital autosomal dominant cataract. Mol Vis (2012) 0.94
cGMP-dependent cone photoreceptor degeneration in the cpfl1 mouse retina. J Comp Neurol (2010) 0.94
Phenotypic variability and long-term follow-up of patients with known and novel PRPH2/RDS gene mutations. Am J Ophthalmol (2008) 0.93
Electrophysiological and histologic assessment of retinal ganglion cell fate in a mouse model for OPA1-associated autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci (2009) 0.93
Isolation of the mouse nyctalopin gene nyx and expression studies in mouse and rat retina. Invest Ophthalmol Vis Sci (2003) 0.93
Variations in the WDR36 gene in German patients with normal tension glaucoma. Mol Vis (2007) 0.93
Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep (2008) 0.93
The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute. Invest Ophthalmol Vis Sci (2012) 0.93
Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA Ophthalmol (2014) 0.92
Ocular surface squamous neoplasia as the first apparent manifestation of HIV infection in Malawi. Clin Experiment Ophthalmol (2008) 0.92
Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Invest Ophthalmol Vis Sci (2011) 0.92
Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations. Invest Ophthalmol Vis Sci (2004) 0.91
Management of conjunctival melanoma. Expert Rev Anticancer Ther (2009) 0.91
Defective mitochondrial adenosine triphosphate production in skeletal muscle from patients with dominant optic atrophy due to OPA1 mutations. Arch Neurol (2010) 0.91
Comparison of formalin-fixed and snap-frozen samples analyzed by multiplex ligation-dependent probe amplification for prognostic testing in uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.91